NASDAQ:BCLI Brainstorm Cell Therapeutics Q1 2026 Earnings Report $0.96 +0.02 (+2.08%) As of 06/25/2026 03:25 PM Eastern ProfileForecast Brainstorm Cell Therapeutics EPS ResultsActual EPSN/AConsensus EPS -$0.28Beat/MissN/AOne Year Ago EPSN/ABrainstorm Cell Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ABrainstorm Cell Therapeutics Announcement DetailsQuarterQ1 2026Date5/15/2026TimeBefore Market OpensConference Call DateFriday, May 15, 2026Conference Call Time7:00AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Company ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Brainstorm Cell Therapeutics Earnings HeadlinesBrainstorm Cell Therapeutics (NASDAQ:BCLI) Stock Crosses Above 200-Day Moving Average - Here's WhyJune 19, 2026 | americanbankingnews.comBrainStorm Cell Therapeutics Announces Publication Calling for Updated FDA Approaches to ALS, Rare Diseases and Regenerative MedicineJune 2, 2026 | prnewswire.comSolar is dead. Here’s what replaces it.Starting July 4th, every new solar and wind project in America loses its federal tax credits. But one zero-carbon energy source retains full government backing for eight more years - and it runs around the clock without batteries. Investment in this sector has surged 100x in seven years. The Pentagon named it a top energy priority, California mandated it, and Google, Meta, and Berkshire Hathaway are already under contract. One company controls the entire chain from the ground to the grid.June 26 at 1:00 AM | Behind the Markets (Ad)BrainStorm Cell Therapeutics Inc.: BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of DirectorsMay 28, 2026 | finanznachrichten.deBrainStorm Adds Former FDA Leader to BoardMay 28, 2026 | tipranks.comBrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of DirectorsMay 28, 2026 | prnewswire.comSee More Brainstorm Cell Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Brainstorm Cell Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Brainstorm Cell Therapeutics and other key companies, straight to your email. Email Address About Brainstorm Cell TherapeuticsBrainstorm Cell Therapeutics (NASDAQ:BCLI) (NASDAQ: BCLI) is a clinical‐stage biotechnology company focused on developing autologous cell therapies for the treatment of neurodegenerative diseases. The company’s proprietary platform leverages mesenchymal stem cells (MSCs) that are engineered to secrete neurotrophic and growth factors designed to support neuronal survival and function. The company’s lead product candidate, NurOwn, is an autologous MSC therapy currently in advanced clinical development for amyotrophic lateral sclerosis (ALS). NurOwn has received orphan drug designations in multiple jurisdictions and is being evaluated in a pivotal clinical program. In addition to ALS, BrainStorm is exploring potential applications of its cell therapy platform in other neurodegenerative disorders such as multiple sclerosis and Parkinson’s disease. Founded in 2000 and headquartered in Petach Tikva, Israel, BrainStorm maintains research and development operations as well as a current good manufacturing practice (cGMP) cell‐processing facility. The company also operates an office in New York City, facilitating collaborations with U.S. clinical sites and regulatory agencies. This infrastructure supports late‐stage trials and positions BrainStorm for potential commercial supply should regulatory approval be achieved. BrainStorm collaborates with leading academic institutions and regulatory authorities to advance its clinical pipeline while maintaining robust data transparency. Guided by a management team with expertise in regenerative medicine, neurology and biopharmaceutical development, the company aims to address significant unmet medical needs in the global neurodegenerative disease market.View Brainstorm Cell Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Micron’s HBM Surge Could Redefine the AI Growth StoryCarnival's Second Quarter: Is the Stock Still Complicated?Paychex Stock Looks Beaten Down, But Not BrokenWhy KB Home Could Reward Patient Investors LaterWashington’s Quantum Push Puts IBM and IonQ on the ThroneFedEx’s Earnings Drop May Be Missing the Bigger Freight Story2 Space and Defense Stocks Turning Backlogs Into Revenue Growth Upcoming Earnings NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)ASML (7/15/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
